NEW YORK (GenomeWeb) – Swiss contract research firm Intomics said today that it has inked an agreement to collaborate with Actelion Pharmaceuticals on research into neurodegenerative diseases.

Intomics said that the partners will apply a systems biology approach to gain a better understanding of the pathological processes underlying human neurodegenerative diseases at the molecular level with a long-term goal of facilitating better treatments for patients with such diseases.

Terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.